A SECOND “game-changing” Alzheimer’s drug shown to slow the progression of the disease has been approved in the UK. Donanemab, developed by pharmaceutical giant Eli Lilly, was ...
Nexalin's DIFS treatment improved memory and cognition in Alzheimer's ... “Our DIFS technology shows great promise as a drug-free alternative or in combination with existing treatments by ...